Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
29 hedge funds and large institutions have $3.76M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
72% more capital invested
Capital invested by funds: $2.19M → $3.76M (+$1.58M)
21% more funds holding
Funds holding: 24 → 29 (+5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$390K |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$92.6K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$43.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.2K |
| 5 |
LPL Financial
San Diego,
California
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$106K |
| 2 |
VF
Virtu Financial
New York
|
-$32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$684 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$26 |
BLCM Hedge Fund Activity: Q1 2022 in Review
29 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2022, worth a combined $3.76M — up 72% from $2.19M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BLCM positions and 3 closed out — a net gain of 5 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Long Focus Capital Management, opening a new position worth an estimated $390K. The largest seller was Vanguard Group, cutting an estimated $106K.
- 29 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2022, up from 24 in Q4 2021.
- Funds reported $3.76M of Bellicum Pharmaceuticals, Inc. stock for Q1 2022, up 72% quarter-over-quarter.
- 8 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2022 and 3 closed out, a net change of +5 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2022 was Long Focus Capital Management, an estimated $390K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2022 was Vanguard Group, an estimated $106K sold.
Based on aggregated 13F filings for Q1 2022.